Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Medical University of South Carolina
Yale University
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Seagen Inc.
Seagen Inc.
Fulgent Pharma LLC.
University of Erlangen-Nürnberg Medical School
University of Kentucky
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Second Affiliated Hospital, School of Medicine, Zhejiang University
University of Michigan Rogel Cancer Center
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Gilead Sciences
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University of Pittsburgh
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine